Telix Pharmaceuticals (NASDAQ: TLX) expands board with two new NEDs
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Telix Pharmaceuticals Limited has expanded its Board by appointing two additional Non-Executive Directors, effective May 11, 2026, as part of broader succession planning. Maria Rivas, MD brings more than 25 years of experience in late-stage clinical development and commercialization, including service as Chief Medical Officer at Pfizer.
William (Bill) Jellison adds over 30 years of corporate finance and audit committee leadership, having served as Vice President and CFO of Stryker and as a director for multiple U.S. public companies. Telix’s Interim Chair said these appointments support the company’s evolution as a dual-listed, global, commercial-stage biopharmaceutical business focused on radiopharmaceuticals for oncology and rare diseases.
Positive
- None.
Negative
- None.
Key Figures
Effective date of appointments: May 11, 2026
Rivas industry experience: More than 25 years
Jellison industry experience: Over 30 years
+2 more
5 metrics
Effective date of appointments
May 11, 2026
Effective date for two new Non-Executive Directors, subject to Director IDs
Rivas industry experience
More than 25 years
Experience in late-stage clinical development, commercialization and governance
Jellison industry experience
Over 30 years
Corporate finance and audit committee leadership in large regulated environments
Global operations staff scale
Several thousand staff
Scale of global operations previously managed by Maria Rivas
Countries of operation
Multiple regions
Operations in US, UK, Brazil, Canada, Europe and Japan
Key Terms
Non-Executive Director, radiopharmaceuticals, forward-looking statements, dual-listed, +1 more
5 terms
Non-Executive Director financial
"Telix Pharmaceuticals Limited today announces two additional Non-Executive Director (NED) appointments"
A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.
radiopharmaceuticals medical
"focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need"
Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.
forward-looking statements regulatory
"This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
dual-listed financial
"well aligned with Telix’s evolution as a dual-listed, global, commercial stage biopharmaceutical company"
succession planning financial
"two additional Non-Executive Director (NED) appointments, effective May 11, 2026, as part of Board expansion and succession planning"
A company’s plan for identifying and preparing people to take over key roles when leaders leave, retire, or are unable to work. Like a sports team’s bench and playbook, it ensures someone ready can step in quickly so operations, strategy and investor confidence aren’t disrupted; investors watch it because solid succession planning reduces the risk of sudden leadership gaps that can hurt performance and stock value.
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 Telix Strengthens Board with Additional Director Appointments Melbourne (Australia) and Indianapolis, IN (U.S.) – April 9, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: • Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years’ experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ: COO), a medical technology company, and also served as an independent director for Medidata (NASDAQ: MDSO) from 2018-2019 until its successful merger with Dassault Systèmes. Dr. Rivas spent over 25 years in healthcare developing and commercializing medical devices and pharmaceutical products across multiple therapeutic areas including oncology, rare diseases and neurosciences, most recently as Chief Medical Officer at Pfizer, Inc. (NYSE: PFE). She has managed global operations of several thousand data scientists, healthcare experts and field staff, and overseen the launch of multiple blockbuster medical products. Dr. Rivas holds a B.A. in Biochemistry from Brandeis University and an MD from Columbia University’s Vagelos College of Physicians and Surgeons. She completed residency training in Internal Medicine and a fellowship in Endocrinology at New York-Presbyterian Hospital. • William (Bill) Jellison is a public company director and corporate finance leader with over 30 years’ experience, including audit committee leadership in large, regulated operating environments. He currently serves on the board of directors of Medtronic plc (NYSE: MDT), Anika Therapeutics, Inc. (NASDAQ: ANIK), Avient Corporation (NYSE: AVNT), Solenis LLC, and Young Innovations, Inc., and until recently served as a director of Masimo Corporation (NASDAQ: MASI). During his executive career, Mr. Jellison most recently served as Vice President and CFO of Stryker Corporation (NYSE: SYK), overseeing international finance, SEC reporting, mergers and acquisitions, and capital allocation. He holds a B.A. in Business Administration from Hope College. Telix Interim Chair, Dr. Mark Nelson, commented on the appointments, “We are delighted to welcome Maria and Bill, highly accomplished Non-Executive Directors whose collective experience in U.S. public company governance, financial oversight and clinical leadership will significantly enhance the Board’s capability. Along with the recent addition of David Gill, these appointments are well aligned with Telix’s evolution as a dual-listed, global, commercial stage biopharmaceutical company.” About Telix Pharmaceuticals Limited Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). 1 Subject to grant of Australian Director Identification numbers.
Page 2 Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com Media Contact Eliza Schleifstein 917.763.8106 (Mobile) Eliza@schleifsteinpr.com This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors. Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2026 Telix Pharmaceuticals Limited. All rights reserved.
FAQ
What board changes did Telix Pharmaceuticals (TLX) announce in this 6-K?
Telix Pharmaceuticals announced two additional Non-Executive Director appointments, effective May 11, 2026. The new directors, Maria Rivas, MD and William Jellison, join as part of Telix’s board expansion and succession planning to support its growth as a dual-listed global biopharmaceutical company.
Who is Maria Rivas and what experience does she bring to Telix (TLX)?
Maria Rivas, MD is an experienced public company director and senior pharmaceutical executive with more than 25 years’ experience. She has held leadership roles in late-stage clinical development and commercialization and most recently served as Chief Medical Officer at Pfizer, overseeing global operations and multiple blockbuster product launches.
What is William Jellison’s background and new role at Telix Pharmaceuticals (TLX)?
William (Bill) Jellison joins Telix as a Non-Executive Director, bringing over 30 years’ corporate finance experience. He previously served as Vice President and CFO of Stryker, where he oversaw international finance, SEC reporting, mergers and acquisitions, and capital allocation, and serves on several U.S. public company boards.
When do the new Telix Pharmaceuticals (TLX) director appointments become effective?
The two new Non-Executive Director appointments at Telix are effective May 11, 2026, subject to the grant of Australian Director Identification numbers. This timing aligns with the company’s broader board expansion and succession planning to support its development as a global commercial-stage biopharmaceutical company.
What does Telix Pharmaceuticals (TLX) focus on as a business?
Telix Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing radiopharmaceuticals to address unmet medical needs in oncology and rare diseases. Headquartered in Melbourne, it operates across the United States, Europe, Brazil, Canada, Japan and is listed on both the ASX and Nasdaq Global Select Market.
Where can investors find more information about Telix Pharmaceuticals (TLX)?
Investors can visit www.telixpharma.com for share price information, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications. Telix also shares updates through LinkedIn, X and Facebook, and provides dedicated investor relations contacts for global, Australian and U.S. stakeholders.